Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Core Viewpoint - Atara Biotherapeutics is under investigation for potential securities fraud following a significant setback with the FDA regarding its EBVALLO treatment, which has led to a substantial decline in stock price and workforce reduction [1][2][3]. Company Developments - On January 16, 2025, Atara Biotherapeutics received a Complete Response Letter (CRL) from the FDA for its EBVALLO treatment, which is intended for patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease [2]. - The CRL was related to observations from a standard pre-license inspection of a third-party manufacturing facility, leading to a clinical hold on Atara's Investigational New Drug applications, including the allogeneic CD19 CAR T therapy ATA3219 [2]. - Following the FDA's decision, Atara's stock price fell by $4.82 per share, closing at $7.62, marking a 39% decline [3]. - The company announced plans to cut 50% of its workforce by June 2025 in response to these challenges [3]. Legal and Regulatory Context - Wolf Haldenstein Adler Freeman & Herz LLP is investigating claims on behalf of Atara's investors regarding potential securities fraud by the company and its officers or directors [1].